Lenalidomide in Combination With CHOP in Patients With Untreated PTCL
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that
single agent lenalidomide showed promising therapeutic activity in patients with relapsed or
refractory PTCL. The investigators therefore design this phase II study to investigate the
safety and efficacy of lenalidomide in combination with CHOP in patients with treatment-naive
PTCL.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University